Graduate School, Bengbu Medical College, 2600 Donghai Road, Bengbu, 233000, Anhui, China.
The Key Laboratory, The Second Affiliated Hospital of Jiaxing University, 1518 North Huancheng Road, Jiaxing, 314000, Zhejiang, China.
BMC Infect Dis. 2023 Oct 20;23(1):711. doi: 10.1186/s12879-023-08671-5.
To identify risk factors for infection complications in patients with gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) and nodal DLBCL (N-DLBCL) during treatment, respectively.
Total 51 GI-DLBCL patients and 80 N-DLBCL patients were included after retrieving clinical data from a single medical center in the past ten years. Logistic regression analysis was utilized to analyze patients' data, including baseline demographics, treatments and laboratory values, to determine independent risk factors of infection in these patients.
Total 28 of 51 patients (54.9%) in the GI-DLBCL group and 52 of 80 patients (65%) in the N-DLBCL group were observed infection events during treatment. A multivariate logistic regression model revealed that Ann-arbor stage IV (P = 0.034; odds ratio [OR]: 10.635; 95% confidence interval [CI]: 1.152-142.712), extra-nodal lesions ≥ 2 (P = 0.041; OR: 23.116; 95%CI: 1.144-466.949) and high serum lactate dehydrogenase (LDH) at the time of diagnosis (LDH > 252U/L; P = 0.033; OR: 6.058; 95%CI: 1.159-31.659) were independent risk factors for the development of infection in patients with GI-DLBCL after systemic treatment. In the N-DLBCL group, high serum C-reactive protein (CRP) (P = 0.027; OR: 1.104; 95%CI: 1.011-1.204) and a low platelet count (P = 0.041; OR: 0.991; 95%CI: 0.982-1.000) at routine blood tests just before infection occurred were identified as significant risk factors related to infection events during treatment.
Discordant independent risk factors induced infection may be present during the treatment in patients with GI-DLBCL and N-DLBCL. Close monitoring these risk factors is likely an effective strategy to prevent microbial infections in these patients.
分别确定胃肠道弥漫性大 B 细胞淋巴瘤（GI-DLBCL）和结外弥漫性大 B 细胞淋巴瘤（N-DLBCL）患者在治疗期间感染并发症的危险因素。
通过检索过去十年中单个医疗中心的临床资料，共纳入 51 例 GI-DLBCL 患者和 80 例 N-DLBCL 患者。利用逻辑回归分析对患者的基线人口统计学、治疗和实验室值等数据进行分析，以确定这些患者感染的独立危险因素。
在 GI-DLBCL 组中，有 28 例（54.9%）患者和 N-DLBCL 组中有 52 例（65%）患者在治疗期间发生感染事件。多变量逻辑回归模型显示，Ann-arbor 分期 IV（P=0.034；比值比[OR]：10.635；95%置信区间[CI]：1.152-142.712）、结外病变≥2 个（P=0.041；OR：23.116；95%CI：1.144-466.949）和初诊时血清乳酸脱氢酶（LDH）升高（LDH＞252U/L；P=0.033；OR：6.058；95%CI：1.159-31.659）是 GI-DLBCL 患者系统性治疗后发生感染的独立危险因素。在 N-DLBCL 组中，在感染发生前常规血液检查中发现高血清 C 反应蛋白（CRP）（P=0.027；OR：1.104；95%CI：1.011-1.204）和血小板计数低（P=0.041；OR：0.991；95%CI：0.982-1.000）是与治疗期间感染事件相关的显著危险因素。
GI-DLBCL 和 N-DLBCL 患者在治疗期间可能存在导致感染的不同独立危险因素。密切监测这些危险因素可能是预防这些患者发生微生物感染的有效策略。
